Because of the unique nature of the materials involved (cells and other hydrogel bioinks), bioprinting can be considered a stand-alone area of additive manufacturing. As such, it also sometimes overlaps with more traditional 3D printing technologies and materials, such as ceramics and resorbable polymers, for implants and scaffolds.
The long-term potential of bioprinting is as large if not larger than the entire potential of industrial additive manufacturing, with significant implications on human life-expectancy and quality of life. This however is something that will likely take place several decades from today.
The current reality is that no commercial bioprinted products – such as organ/tissue transplants and grafts – are yet available on the market for consumer regenerative medicine. Nevertheless, these technologies and processes are already having a massive impact on regenerative medicine and pharmaceutical research.
Mapping and categorizing bioprinting technologies is challenging since most systems integrate hybrid versions of extrusion, material jetting and even photopolymerization as well as other approaches that are not used in industrial manufacturing such as acoustic and magnetic assembly.
One general element to consider is that bioprinting is primarily divided into indirect technologies, used to build polymeric scaffolds upon which to add the cellular materials, and technologies that assemble the cellular materials directly. Scaffolds can be compared to tools in industrial manufacturing: as such these technologies are likely to be the first to enable the production of complex, vascularized organs and tissues. On the other hand, direct bioprinting technologies represent the ultimate goal of bioassembly and bioengineering, with volumetric approaches (where a part is built by consolidating all sides at the same time, not just one 2D layer at a time) seen as the key to the production of entire organs.
One related area that is emerging very rapidly is cellular agriculture, which is the ability to produce meat and dairy products directly from lab-grown cells. Using bioprinters to assemble these cells can become an effective way to give cellular agriculture products the look and shape of animal-derived equivalents.
Commercial implementation of bioprinting technologies is already underway in the fields of drug development testing (DDT) and cosmetics development and testing. Adoption has also been booming within the regenerative and bioengineering areas of research at major academic institutions operating in these fields around the world, which has driven the development and sale of an increasing number of bioprinting systems, based on several different additive processes.
Although complex organ production for human transplant remains a very long term objective, simpler bioprinted organs and tissue grafting for human use now seem increasingly within reach, especially for cartilage, bone, and skin. The latest breakthrough in lung regeneration technology, which saw the involvement of traditional 3D printing firm 3D Systems, provides an indication for future production of commercially available complex bioprinted organs for human transplant.
The map above categorizes the companies that have developed and commercialized bioprinting hardware or bioprinted products based on internally developed bioprinting technologies. If you’d like to see a company added to this map, write us at firstname.lastname@example.org.
Both bioprinting technologies and materials (bioinks) are evolving rapidly and in many different directions, making the segment difficult to accurately map and track. 3dpbm’s 3D Printing Business Directory lists just over 100 active companies and three primary categories: 19% are bioink (and generally bioprinting materials) manufacturers, 39% are bioprinting hardware manufacturers and 42% are bioprinting service providers. As is the case in many other fringe areas of AM, such as construction and advanced materials, several technology developers use their proprietary hardware to provide services and parts. This category of companies also includes university laboratories and internal laboratories within pharmaceutical firms that leverage bioprinting to provide services.
In this month’s AM Focus Bioprinting, we will present some of the latest innovations in this segment. We will also take a much closer look at some of the companies that are driving innovation in bioprinting by contributing to widening access to these technologies and their applications.
State of the deep tech industry, from start-up to venture capital
The industry of deep tech is a ferocious beast, prowling the shadows of innovation with intense hunger. It’s an exciting adventure, filled with many risks & rewards, where the only…
Redwire’s upgraded BFF 3D bioprinter installed on ISS
Redwire’s BFF, the 3D BioFabrication Facility is America’s first bioprinter with a permanent home on the International Space Station (ISS). In early 2023, NASA astronauts successfully installed an upgraded BFF…
Low endotoxin biomaterials will help reduce animal testing
Darling Ingredients’ health brand Rousselot, the global leader in collagen-based solutions, released a new study in collaboration with the University of Twente. The study demonstrated found that the utilization of…
Scientists 3D print using sound waves
Scientists from the Micro, Nano, and Molecular Systems Lab at the Max Planck Institute for Medical Research and the Institute for Molecular Systems Engineering, and Advanced Materials at Heidelberg University…
3D Systems launches Regenerative Tissue Program
3D Systems (NYSE:DDD) introduced its Regenerative Tissue Program intended to provide an unparalleled solution for surgical procedures requiring reconstruction. 3D Systems has established this program as a result of the…
The state of bioprinting
We have been covering 3D bioprinting for nearly a decade, starting back when the bioprinting industry began to expand beyond high-end systems used exclusively for academic research into a young…
NEI researchers 3D bioprint eye tissue
Scientists from the National Eye Institute (NEI), part of the National Institutes of Health, have used patient stem cells and 3D bioprinting to produce eye tissue that will advance the…
Essent Biologics launches micronized bone matrix for 3D bioprinting
Essent Biologics, a leading supplier of human-derived cell and scaffold materials, launched its new Micronized Bone Matrix (MBM) for 3D bioprinting and tissue engineering applications. Essent Biologics will provide a…
The Promised Land of 3D printing
The Promised Land is generally intended as the land of Israel, which, according to the Bible’s Old Testament, God promised and subsequently gave to Abraham and several more times to…
Steakholder Foods develops temperature-controlled print bed
Steakholder Foods Ltd. (Nasdaq: STKH), (formerly MeaTech 3D: MITC), an international deep-tech food company at the forefront of the cultivated meat industry, developed a temperature-controlled print bed for its industrial-scale…